
Recent trials in cardiovascular medicine have contradicted current practice, and, zzso are medical zzso zzso zzso and zzso have failed to provide mortality benefit when added to zzso therapy, though both drugs have been used for this purpose for zzso zzso primary prevention is no small zzso Annual spending on statins exceeded $19 billion in 2005, zzso cost over $5 billion in 2007, and zzso costs passed $1 billion in zzso Given the tremendous price of these medications, and recent trials that have undermined years of practice, we propose that the bar for cardiovascular primary prevention has been zzso Large studies must show improvements in overall mortality before novel agents are recommended and zzso The implications of this proposal are zzso 

